Suppr超能文献

哮喘结局:医疗保健利用和成本。

Asthma outcomes: healthcare utilization and costs.

机构信息

National Center for Health Statistics, Center for Disease Control and Prevention, Hyattsville, MD, USA.

出版信息

J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S49-64. doi: 10.1016/j.jaci.2011.12.984.

Abstract

BACKGROUND

Measures of healthcare utilization and indirect impact of asthma morbidity are used to assess clinical interventions and estimate cost.

OBJECTIVE

National Institutes of Health institutes and other federal agencies convened an expert group to propose standardized measurement, collection, analysis, and reporting of healthcare utilization and cost outcomes in future asthma studies.

METHODS

We used comprehensive literature reviews and expert opinion to compile a list of asthma healthcare utilization outcomes that we classified as core (required in future studies), supplemental (used according to study aims and standardized), and emerging (requiring validation and standardization). We also have identified methodology to assign cost to these outcomes. This work was discussed at an National Institutes of Health-organized workshop in March 2010 and finalized in September 2011.

RESULTS

We identified 3 ways to promote comparability across clinical trials for measures of healthcare utilization, resource use, and cost: (1) specify the study perspective (patient, clinician, payer, and society); (2) standardize the measurement period (ideally 12 months); and (3) use standard units to measure healthcare utilization and other asthma-related events.

CONCLUSIONS

Large clinical trials and observational studies should collect and report detailed information on healthcare utilization, intervention resources, and indirect impact of asthma, so that costs can be calculated and cost-effectiveness analyses can be conducted across several studies. Additional research is needed to develop standard, validated survey instruments for collection of provider-reported and participant-reported data regarding asthma-related health care.

摘要

背景

医疗保健利用和哮喘发病率的间接影响的衡量标准用于评估临床干预措施并估算成本。

目的

美国国立卫生研究院(NIH)及其它联邦机构召集专家组,提议对未来哮喘研究中医疗保健利用和成本结果进行标准化的测量、收集、分析和报告。

方法

我们综合文献回顾和专家意见,编制了一份哮喘医疗保健利用结果清单,将其分为核心(未来研究中必需的)、补充(根据研究目的和标准化使用)和新兴(需要验证和标准化)类别。我们还确定了为这些结果分配成本的方法。这项工作在 2010 年 3 月由 NIH 组织的研讨会上进行了讨论,并在 2011 年 9 月最终确定。

结果

我们确定了 3 种方法来促进临床试验中医疗保健利用、资源利用和成本措施的可比性:(1)指定研究视角(患者、临床医生、支付方和社会);(2)标准化测量期(理想情况下为 12 个月);(3)使用标准单位来衡量医疗保健利用和其它与哮喘相关的事件。

结论

大型临床试验和观察性研究应收集和报告有关医疗保健利用、干预资源和哮喘间接影响的详细信息,以便计算成本并进行多项研究的成本效益分析。需要进一步研究以开发用于收集提供者报告和参与者报告的与哮喘相关的医疗保健数据的标准、经过验证的调查工具。

相似文献

1
Asthma outcomes: healthcare utilization and costs.
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S49-64. doi: 10.1016/j.jaci.2011.12.984.
2
Asthma outcomes workshop: overview.
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S1-8. doi: 10.1016/j.jaci.2011.12.985.
3
Asthma outcomes: exacerbations.
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S34-48. doi: 10.1016/j.jaci.2011.12.983.
4
Economic impact of severe asthma in Spain: multicentre observational longitudinal study.
J Asthma. 2019 Aug;56(8):861-871. doi: 10.1080/02770903.2018.1499035. Epub 2018 Oct 9.
5
Healthcare costs and resource utilization of asthma in Germany: a claims data analysis.
Eur J Health Econ. 2016 Mar;17(2):195-201. doi: 10.1007/s10198-015-0671-3. Epub 2015 Feb 26.
6
Asthma outcomes: composite scores of asthma control.
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S24-33. doi: 10.1016/j.jaci.2011.12.980.
7
Economic burden of severe asthma in Turkey: a cost of illness study from payer perspective.
Eur Ann Allergy Clin Immunol. 2021 May;53(3):128-137. doi: 10.23822/EurAnnACI.1764-1489.149. Epub 2020 May 6.
9
Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
J Allergy Clin Immunol Pract. 2018 Mar-Apr;6(2):619-632. doi: 10.1016/j.jaip.2017.07.028. Epub 2017 Sep 28.
10
Cost-effectiveness of asthma therapy: a comprehensive review.
J Asthma. 2015;52(6):529-37. doi: 10.3109/02770903.2014.999283. Epub 2015 Jul 25.

引用本文的文献

1
Cost-effectiveness of school integrated pest management and air filtration in students with asthma.
Allergy Asthma Proc. 2025 May 1;46(3):257-266. doi: 10.2500/aap.2025.46.250018.
2
Medicaid Accountable Care Organizations and Disparities in Pediatric Asthma Care.
JAMA Pediatr. 2024 Nov 1;178(11):1208-1215. doi: 10.1001/jamapediatrics.2024.3935.
3
Coordinated Health Care Interventions for Childhood Asthma Gaps in Outcomes (CHICAGO) plan.
J Allergy Clin Immunol Glob. 2023 Aug;2(3). doi: 10.1016/j.jacig.2023.100100.
4
Bronchial epithelial cell transcriptional responses to inhaled corticosteroids dictate severe asthmatic outcomes.
J Allergy Clin Immunol. 2023 Jun;151(6):1513-1524. doi: 10.1016/j.jaci.2023.01.028. Epub 2023 Feb 14.
5
Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).
Eur Respir J. 2023 Apr 3;61(4). doi: 10.1183/13993003.00606-2022. Print 2023 Apr.
7
Translational Effect of Provider-Focused, Multi-State, Multi-Clinic Asthma Care Quality Improvement Program on Patient-Level Health Care Costs.
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211000246. doi: 10.1177/21501327211000246.
9
Developing core economic parameter sets for asthma studies: a realist review and an analytical framework.
BMJ Open. 2020 Oct 20;10(10):e037889. doi: 10.1136/bmjopen-2020-037889.
10
The home air in agriculture pediatric intervention (HAPI) trial: Rationale and methods.
Contemp Clin Trials. 2020 Sep;96:106085. doi: 10.1016/j.cct.2020.106085. Epub 2020 Jul 25.

本文引用的文献

1
The AMCP format for formulary submissions version 3.0.
J Manag Care Pharm. 2010 Jan;16(1 Suppl A):1-30. doi: 10.18553/jmcp.2010.16.S1-A.1.
2
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda.
BMC Health Serv Res. 2009 Oct 21;9:192. doi: 10.1186/1472-6963-9-192.
8
Quality of care for childhood asthma: estimating impact and implications.
Pediatrics. 2009 Mar;123 Suppl 3:S199-204. doi: 10.1542/peds.2008-2233K.
9
Status of childhood asthma in the United States, 1980-2007.
Pediatrics. 2009 Mar;123 Suppl 3:S131-45. doi: 10.1542/peds.2008-2233C.
10
Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Hemodial Int. 2008 Oct;12(4):441-9. doi: 10.1111/j.1542-4758.2008.00308.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验